Primary Sclerosing Cholangitis Market - 2026-2033

March 2026 | 56 pages | ID: P9E58CC0817BEN
DataM Intelligence

Abstracts

Primary Sclerosing Cholangitis Market reached US$ 385.67 million in 2025 and is expected to reach US$ 987.26 million by 2033, growing with a CAGR of 12.21% during the forecast period 2026-2033.

The Primary Sclerosing Cholangitis Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Primary Sclerosing Cholangitis Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Treatment

• Medication-based Therapies*
• Bile acid sequestrants
• Antibiotics
• Antihistamines
• Opioid antagonists
• Ursodeoxycholic acid (UDCA)
• Bile Duct Blockages
• Balloon dilation
• Stent placement
• Liver Transplantation

By Disease Stage

• Early-stage*
• Moderate-stage
• Advanced-stage

By Patient Age

• Child*
• Adult

By End-User

• Hospitals*
• Specialty Clinics
• Others

Regional Analysis for Primary Sclerosing Cholangitis Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Primary Sclerosing Cholangitis Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Treatment
3.2. Snippet by Disease Stage
3.3. Snippet by Patient Age
3.4. Snippet by End-User
3.5. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Rising prevalence of primary sclerosing cholangitis
  4.1.2. Restraints
    4.1.2.1. Side effects associated with primary sclerosing cholangitis
  4.1.3. Opportunity
    4.1.3.1. Technological advancements
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Russia-Ukraine Analysis
5.8. Artificial Intelligence Impact

6. COVID-19 ANALYSIS

6.1. Analysis of COVID-19
  6.1.1. Scenario Before COVID-19
  6.1.2. Scenario During COVID-19
  6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion

7. BY TREATMENT

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  7.1.2. Market Attractiveness Index, By Treatment
7.2. Medication-based Therapies*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  7.2.3. Bile acid sequestrants
  7.2.4. Antibiotics
  7.2.5. Antihistamines
  7.2.6. Opioid antagonists
  7.2.7. Ursodeoxycholic acid (UDCA)
7.3. Bile Duct Blockages
  7.3.1. Balloon dilation
  7.3.2. Stent placement
7.4. Liver Transplantation

8. BY DISEASE STAGE

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  8.1.2. Market Attractiveness Index, By Disease Stage
8.2. Early-stage*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Moderate-stage
8.4. Advanced-stage

9. BY PATIENT AGE

9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
9.2. Market Attractiveness Index, By Patient Age
9.3. Child*
  9.3.1. Introduction
  9.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.4. Adult

10. BY END-USER

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Others

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.7.1. U.S.
    11.2.7.2. Canada
    11.2.7.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.7.1. Germany
    11.3.7.2. U.K.
    11.3.7.3. France
    11.3.7.4. Italy
    11.3.7.5. Spain
    11.3.7.6. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.7.1. Brazil
    11.4.7.2. Argentina
    11.4.7.3. Rest of South America
11.5. Asia-Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.7.1. China
    11.5.7.2. India
    11.5.7.3. Japan
    11.5.7.4. Australia
    11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies

13. COMPANY PROFILES

13.1. Chemomab Therapeutics Ltd.*
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Financial Overview
  13.1.4. Key Developments
13.2. Mirum Pharmaceuticals, Inc.
13.3. Ipsen S.A.
13.4. GENFIT
13.5. Gilead Sciences, Inc.
13.6. Pliant Therapeutics, Inc.
13.7. Immunic, Inc.
13.8. Dr. Falk Pharma GmbH
13.9. SCOHIA PHARMA, Inc.
13.10. Sirnaomics Ltd. (LIST NOT EXHAUSTIVE)

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us